Eli Lilly Announces Tirzepatide Cuts Diabetes Risk by 94% in Three-Year Study
Eli Lilly's tirzepatide shows a 94% reduction in diabetes risk and significant weight loss in adults with pre-diabetes and obesity, according to a three-year study.
Changing Trends in GLP-1 Drug Use: Who's Taking Them and Why?
Explore the shift in GLP-1 drug use as a growing number of non-diabetics turn to these medications for weight loss. Understand the new trends and their impact on diabetes care.